Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4773352 | 0.88 | HDAC2 (0.60) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL4769805 | 0.86 | HDAC2 (0.62) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL4291654 | 0.78 | TAAR1 (0.52) | ALOX5TAAR1TDP1MEN1NPC1 | |
| SCHEMBL2500291 | 0.78 | TSHR (0.44) | HDAC2HDAC8HDAC6HDAC1NPC1 | |
| SCHEMBL6260576 | 0.78 | CHRNA7 (0.57) | TDP1CYP1A2CYP2D6 | |
| SCHEMBL5526488 | 0.75 | TAAR1 (0.59) | TAAR1TDP1MEN1NPC1RAB9A | |
| SCHEMBL3240874 | 0.75 | TAAR1 (0.48) | ALOX5TAAR1TDP1MEN1NPC1 | |
| SCHEMBL7456364 | 0.75 | AOC3 (0.55) | ALOX5TAAR1TDP1MEN1NPC1 | |
| SCHEMBL1300014 | 0.75 | TAAR1 (0.59) | TAAR1TDP1MEN1NPC1RAB9A | |
| SCHEMBL4968152 | 0.75 | CYP1A2 (0.62) | ALOX5TAAR1TDP1MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | claimed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | claimed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| EP-1539159-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1531821-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNYL MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | Astrazeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006926-A1 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ARYL OR HETEROARYL GROUP FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006927-A2 | SULPHONYLPIPERIDINE DERIVATIVES CONTAINING AN ALKENYL OR ALKYNLY MOIETY FOR USE AS MATRIX METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| EP-0171217-A2 | Fused-ring heterocyclic compounds a process for their production and their pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1986-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | HDAC2 1411/4885HDAC8 1938/4885HDAC6 1886/4885 |
| US-20060173041-A1 | Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors | MMP9, MMP2, MMP25 | HDAC2 82/4885HDAC8 328/4885HDAC6 105/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | HDAC2 324/4885HDAC8 1433/4885HDAC6 830/4885 |
| US-20060142336-A1 | N-sulfonylpiperidines as metalloproteinase inhibitors (tace) | ADAM10, ADAM9, CTRL | HDAC2 832/4885HDAC8 1016/4885HDAC6 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.